Please ensure Javascript is enabled for purposes of website accessibility

Why AnaptysBio Was a Stock Market Star on Friday

By Eric Volkman - Feb 26, 2021 at 6:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There was some encouraging news from across the Atlantic.

What happened

AnaptysBio (ANAB -1.20%) closed more than 10% higher on Friday. This followed news that a drug the company partnered on has received a positive opinion from an important multinational health agency.

So what

On Friday, the European Union's (EU) European Medicines Agency's Committee for Medicinal Products for Human Use recommended that the EU grant conditional marketing authorization for Jemperli (dostarlimab). This is an immunotherapy drug being developed by GlaxoSmithKline (GSK -1.22%) that treats recurrent or advanced endometrial cancer.

GlaxoSmithKline, a global pharmaceutical company, has partnered with immunotherapy specialist AnaptysBio on that drug and several other pipeline medicines. In all cases, AnaptysBio-generated antibodies are being utilized in those treatments.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

As AnaptysBio is a clinical-stage biotech, so at the moment it relies on collaboration revenue. This is why, in the Q4 of fiscal 2020 results released Thursday afternoon, GlaxoSmithKline was responsible for every penny of its $60 million in total revenue.

This stems from a one-time payment from another cancer drug, Zejula, which treats ovarian, fallopian tube, and peritoneal cancer. As of the beginning of this year, GlaxoSmithKline is paying a 1% royalty on global net sales of Zejula.

Now what

If dostarlimab is ultimately authorized by the EU, AnaptysBio will be on the hook to receive 8% to as much as 25% of its global net sales. The U.S. Food and Drug Administration is also evaluating the drug. Since the company anticipates the FDA will grant its first approval for the drug later this year, its future seems bright.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
AnaptysBio
ANAB
$18.96 (-1.20%) $0.23
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$44.42 (-1.22%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.